Notes
funded by Amgen
Reference
Stollenwerk B, et al. Assessing the Cost-Utility of Etelcalcetide: a Markov Model. 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PUK18, 29 Oct 2016. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=47693
Rights and permissions
About this article
Cite this article
Model suggests etelcalcetide cost effective for SHPT in Europe. PharmacoEcon Outcomes News 767, 20 (2016). https://doi.org/10.1007/s40274-016-3580-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3580-5